FIELD: medicine.
SUBSTANCE: invention relates to pharmaceutical compositions intended for tumor treatment. Composition contains two different monoclonal antibody molecules: MAb 425 and MAb 225 in mouse, chimeric or humanised modification, each of which contains epitopes simultaneously binding with different sites within one and the same binding ligand domain receptor ErbB1. Composition can cause increase of transverse binding of different or similar ErbB receptors and enhance induction of modulation of specific way of signal transmission.
EFFECT: use of composition allows to reduce doses of compositions and medications applied in tumor therapy, and thus reduce number of side effects resulting from introduction of high doses.
10 cl, 5 ex, 5 dwg
